Market News AIOpen the app

Evotec and Bristol Myers Squibb got FDA approval for their second drug candidate in protein degradation research.

TrialRead the original at prnewswire.com
Good for EVO

Evotec's partnership now has a second FDA-accepted candidate, after the first entered a Phase 1 trial in March 2026. The new candidate is not expected in a Phase 1 trial until 2027, so this shows progress but not a proven treatment.

EVO · Evotec

AI read · Good for EVO

The AI's read

This adds a second candidate to the partnership's early drug development work. The first candidate entered a Phase 1 trial in March 2026, and this one is expected to begin a Phase 1 trial in 2027. These steps show progress, but neither proves the drugs will work in patients.

BMY · Bristol Myers Squibb

AI read · Good for BMY

The connection

Bristol Myers Squibb's partnership with Evotec reached a second FDA-accepted candidate, after the first entered a Phase 1 trial in March 2026. The new candidate is not expected in a Phase 1 trial until 2027, so this is progress, not proof of a working drug.

Get alerts for EVO

Follow Evotec (EVO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EVO
Free on the App Store and Google Play, or on the web.